Literature DB >> 11502540

Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp.

K S Kaye1, S Cosgrove, A Harris, G M Eliopoulos, Y Carmeli.   

Abstract

Among 477 patients with susceptible Enterobacter spp., 49 subsequently harbored third-generation cephalosporin-resistant Enterobacter spp. Broad-spectrum cephalosporins were independent risk factors for resistance (relative risk [OR] = 2.3, P = 0.01); quinolone therapy was protective (OR = 0.4, P = 0.03). There were trends toward decreased risk for resistance among patients receiving broad-spectrum cephalosporins and either aminoglycosides or imipenem. Of the patients receiving broad-spectrum cephalosporins, 19% developed resistance.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11502540      PMCID： PMC90703          DOI： 10.1128/AAC.45.9.2628-2630.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System.

Authors: 
Journal:  Am J Infect Control       Date:  1999-12       Impact factor: 2.918

2.  National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System.

Authors: 
Journal:  Am J Infect Control       Date:  1996-10       Impact factor: 2.918

Review 3.  Microbial resistance to newer generation beta-lactam antibiotics: clinical and laboratory implications.

Authors:  C C Sanders; W E Sanders
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

Review 4.  Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Authors:  W E Sanders; C C Sanders
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

5.  Colonization with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a nonoutbreak period: prevalence, risk factors, and rate of infection.

Authors:  E M D'Agata; L Venkataraman; P DeGirolami; P Burke; G M Eliopoulos; A W Karchmer; M H Samore
Journal:  Crit Care Med       Date:  1999-06       Impact factor: 7.598

6.  Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics.

Authors:  C C Sanders; W E Sanders
Journal:  J Infect Dis       Date:  1986-11       Impact factor: 5.226

7.  Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents.

Authors:  Y Carmeli; N Troillet; G M Eliopoulos; M H Samore
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

8.  The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms.

Authors:  K L Jacobson; S H Cohen; J F Inciardi; J H King; W E Lippert; T Iglesias; C J VanCouwenberghe
Journal:  Clin Infect Dis       Date:  1995-11       Impact factor: 9.079

9.  Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy.

Authors:  J W Chow; M J Fine; D M Shlaes; J P Quinn; D C Hooper; M P Johnson; R Ramphal; M M Wagener; D K Miyashiro; V L Yu
Journal:  Ann Intern Med       Date:  1991-10-15       Impact factor: 25.391

10.  Infections with gram-negative bacilli in a cardiac surgery intensive care unit: the relative role of enterobacter.

Authors:  D M Flynn; R A Weinstein; S A Kabins
Journal:  J Hosp Infect       Date:  1988-02       Impact factor: 3.926
  10 in total
  35 in total

1.  Extended-spectrum beta-lactamases among Enterobacter isolates obtained in Tel Aviv, Israel.

Authors:  Jacob Schlesinger; Shiri Navon-Venezia; Inna Chmelnitsky; Orly Hammer-Münz; Azita Leavitt; Howard S Gold; Mitchell J Schwaber; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacae.

Authors:  Dóra Szabó; Robert A Bonomo; Fernanda Silveira; A William Pasculle; Carla Baxter; Peter K Linden; Andrea M Hujer; Kristine M Hujer; Kathleen Deeley; David L Paterson
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Prevalence of Carbapenemases and Metallo-β-lactamases in Clinical Isolates of Enterobacter Cloacae.

Authors:  Priyanka Banerjee; Tavleen Jaggi; Mehvash Haider; Bibhabati Mishra; Archana Thakur
Journal:  J Clin Diagn Res       Date:  2014-11-20

Review 4.  A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World.

Authors:  Pranita D Tamma; Yohei Doi; Robert A Bonomo; J Kristie Johnson; Patricia J Simner
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

5.  Beyond Susceptible and Resistant, Part I: Treatment of Infections Due to Gram-Negative Organisms With Inducible β-Lactamases.

Authors:  Conan Macdougall
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

6.  Impact of healthcare-associated acquisition on community-onset Gram-negative bloodstream infection: a population-based study: healthcare-associated Gram-negative BSI.

Authors:  M N Al-Hasan; J E Eckel-Passow; L M Baddour
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-08       Impact factor: 3.267

7.  Complex Regulation Pathways of AmpC-Mediated β-Lactam Resistance in Enterobacter cloacae Complex.

Authors:  François Guérin; Christophe Isnard; Vincent Cattoir; Jean Christophe Giard
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

8.  Emergence of Resistance in Klebsiella aerogenes to Piperacillin-Tazobactam and Ceftriaxone.

Authors:  Marco M Custodio; Daniel Sanchez; Beverly Anderson; Keenan L Ryan; Carla Walraven; Renee-Claude Mercier
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

9.  Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species.

Authors:  Mitchell J Schwaber; Camilla S Graham; Bruce E Sands; Howard S Gold; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 10.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.